TY - JOUR
T1 - A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings
AU - Miyasaka, Tomomitsu
AU - Aoyagi, Tetsuji
AU - Uchiyama, Binei
AU - Oishi, Kazunori
AU - Nakayama, Toshinori
AU - Kinjo, Yuki
AU - Miyazaki, Yoshitsugu
AU - Kunishima, Hiroyuki
AU - Hirakata, Yoichi
AU - Kaku, Mitsuo
AU - Kawakami, Kazuyoshi
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan , a Grant from the Ministry of Health, Labor and Welfare of Japan (Research on Emerging and Re-emerging Infectious Diseases), a Grant from the Ministry of Health, Labor and Welfare of Japan (H22-seisakusouyaku-ippan-012) and aid funding from Ohyama Health Foundation, Inc .
PY - 2012/5/9
Y1 - 2012/5/9
N2 - Pneumococcal polysaccharide vaccine (PPV), a type-2 thymus-independent antigen, induces the activation of B cells by directly triggering their antigen receptors. Although this type of antigen generally does not undergo class switching from IgM to IgG, PPV has been known to induce IgG2 in vaccinated subjects, which suggests the possible involvement of certain innate immune lymphocytes supporting the activation of B cells and their class switching. In the present study, we addressed the possibility that natural killer (NK) T cells are involved in Ab production caused by PPV. We measured serum levels of IgG against pneumococcal capsular polysaccharides and the numbers of CD4 +, CD8 + and CD4 -CD8 - double negative (DN) invariant NKT (iNKT) cells and CD3 +CD56 + NKT cells in the peripheral blood before and after PPV injection. IgG was increased after PPV injection, peaking at 4 weeks after injection in serotypes 6B, 19F and 23F and at 3 months in serotype 14. Low responders, whose serum concentrations of IgG peaked at less than double their original levels, constituted 16%, 13%, 13% and 16% of vaccinated subjects with regard to serotypes 6B, 14, 19F and 23F, respectively. A significant positive correlation was detected between an increase in DN iNKT cells and the elevation of anti-serotype 14 IgG; in serotype 19F, DN iNKT cells were more markedly increased in responders than in low responders. These results suggest that DN iNKT cells may be involved in IgG production caused by vaccination against pneumococcal capsular polysaccharides.
AB - Pneumococcal polysaccharide vaccine (PPV), a type-2 thymus-independent antigen, induces the activation of B cells by directly triggering their antigen receptors. Although this type of antigen generally does not undergo class switching from IgM to IgG, PPV has been known to induce IgG2 in vaccinated subjects, which suggests the possible involvement of certain innate immune lymphocytes supporting the activation of B cells and their class switching. In the present study, we addressed the possibility that natural killer (NK) T cells are involved in Ab production caused by PPV. We measured serum levels of IgG against pneumococcal capsular polysaccharides and the numbers of CD4 +, CD8 + and CD4 -CD8 - double negative (DN) invariant NKT (iNKT) cells and CD3 +CD56 + NKT cells in the peripheral blood before and after PPV injection. IgG was increased after PPV injection, peaking at 4 weeks after injection in serotypes 6B, 19F and 23F and at 3 months in serotype 14. Low responders, whose serum concentrations of IgG peaked at less than double their original levels, constituted 16%, 13%, 13% and 16% of vaccinated subjects with regard to serotypes 6B, 14, 19F and 23F, respectively. A significant positive correlation was detected between an increase in DN iNKT cells and the elevation of anti-serotype 14 IgG; in serotype 19F, DN iNKT cells were more markedly increased in responders than in low responders. These results suggest that DN iNKT cells may be involved in IgG production caused by vaccination against pneumococcal capsular polysaccharides.
KW - Antibody production
KW - NKT cells
KW - Pneumococcal polysaccharide vaccine
UR - http://www.scopus.com/inward/record.url?scp=84859823598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859823598&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2012.03.007
DO - 10.1016/j.vaccine.2012.03.007
M3 - Article
C2 - 22426326
AN - SCOPUS:84859823598
VL - 30
SP - 3304
EP - 3310
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 22
ER -